Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03392311
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:36.808279+00:00
Published At
2023-08-24T00:00:00+00:00
Record Updated At
2023-08-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Mesenchymal Stromal Cells", "Psoriasis", "Drug Effect", "Drug Toxicity"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-24"
protocolSection.identificationModule.nctId
"NCT03392311"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Mesenchymal Stromal Cells (protocolSection.conditionsModule.conditions)
  • Psoriasis (protocolSection.conditionsModule.conditions)
  • Drug Effect (protocolSection.conditionsModule.conditions)
  • Drug Toxicity (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.